Posted by Michael Wonder on 20 Jul 2026
Scenesse approved for EPP in Canada
13 July 2026 - Clinuvel's novel drug Scenessa (afamelanotide) has been granted a Notice of Compliance by Health Canada for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria.
The Notice of Compliance acknowledges the compliance of the Scenesse new drug submission with Section C.08.002 and C.08.005 of the Canadian Food and Drug Regulations and grants Clinuvel the right to market Scenesse in Canada.
